Fact CheckerSign in

NCT04039061Recruiting

ADPKD Patient Registry

Autosomal Dominant Polycystic Kidney Disease Patient Registry

Source: ClinicalTrials.gov · Last updated 22 Sept 2026

Brief summary (registry, in English)

The purpose of the ADPKD Registry is to create an online patient network that includes at least 5,000 people with Autosomal Dominant Polycystic Kidney Disease (ADPKD) who contribute data on their health and other topics. The ADPKD Patient Registry aims to support important scientific discoveries and support patient needs in the following ways: * Connect ADPKD patients with opportunities to join clinical studies. * Collect data for the research community to better describe the ADPKD disease experience and improve patient care. * Engage with patients by measuring quality of life outcomes.

Status (registry)
Recruiting
Study type
Observational
Enrollment
3000 (estimated)
First submitted
29 Jul 2019
Start date
Sept 2019
Primary completion date
Sept 2029
Lead sponsor
PKD Foundation
NCT number
NCT04039061

What you commit to

  • Study type: Observational
  • Planned participants: 3000
  • From Sept 2019 to the primary completion date, Sept 2029
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • caretakers, family members or friends of individuals with ADPKD

Who the study is looking for

  • Diagnosis or suspected diagnosis with autosomal dominant polycystic kidney disease (ADPKD)

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
PKD Foundation
Coordinator of this site? Confirm its status
Kansas CityUnited StatesRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.